Panacea Biotec Ltd

NSE: PANACEABIO · BSE: 531349 · Pharmaceuticals & Biotechnology · 28 announcements

Share price: ₹357.10
Market cap: ₹2,187 Cr
Revenue (annual): ₹639.8 Cr
Net profit (annual): ₹-5.37 Cr
P/E (TTM): -307.2×Sector 47.4×
Promoter holding: 72.48%+0.00% QoQ
FII holding: 2.31%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

Announcement type

All Legal & Regulatory 6 Promoter Buying (Off-Market) 3 Other Announcement 3 New Order Win 3 Financial Results 3 Board Meeting Date 2 Management Change 1 Capital Structure Change 1 Annual General Meeting 1 Adverse Business Impact 1

Time

All time Last 1 week Last 1 month Last 2 months Last 3 months Last 6 months Last 1 year

3 announcements with these filters

5 Aug 2026 09:39 IST BSE

New Order Win

Panacea Biotec Bags ₹78.24 Cr Order

Panacea Biotec Ltd secured a Letter of Award from UNICEF worth approximately Rs.78.24 Crore ($8.205 million). The contract involves supplying bivalent Oral Polio Vaccine during 2028.

Value: ₹78.24 Cr
Execution: Calendar Year 2028

Read the filing ↗

8 Jun 2026 18:22 IST NSE

New Order WinAlfa Alert

Panacea Biotec Bags ₹120.9 Cr Order

Panacea Biotec joined the €11.1 million (₹120.90 Crore) EU-funded DENSTAR consortium. The 48-month project advances licensure of its DengiAll vaccine in sub-Saharan Africa.

Value: ₹120.9 Cr
Execution: 48 months

Read the filing ↗

11 Apr 2026 16:01 IST BSE

New Order Win

Panacea Biotec Bags ₹20.79 Cr Order

Panacea Biotec Ltd secured a ₹20.79 Crore contract from the Central Medical Services Society (CMSS) to supply Diphtheria and Tetanus Vaccine (Td Vaccine). Deliveries will occur in several tranches between late 2026 and late 2028, providing steady revenue visibility for the company's vaccine segment.

Value: ₹20.79 Cr
Execution: September / October 2026 till November / December 2028

Read the filing ↗